Synthesis and Intracellular Uptake of Rhodamine–Nucleolipid Conjugates into a Nanoemulsion Vehicle
Anthony Cunha, Geoffrey Prévot, Yannick Mousli, Philippe Barthélémy, Sylvie Crauste-Manciet, Benjamin Dehay, Valérie Desvergnes

To cite this version:
Anthony Cunha, Geoffrey Prévot, Yannick Mousli, Philippe Barthélémy, Sylvie Crauste-Manciet, et al.. Synthesis and Intracellular Uptake of Rhodamine–Nucleolipid Conjugates into a Nanoemulsion Vehicle. ACS Omega, ACS Publications, 2020, 5 (11), pp.5815-5823. 10.1021/acsomega.9b03992 . hal-02991995

HAL Id: hal-02991995
https://hal.archives-ouvertes.fr/hal-02991995
Submitted on 20 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Synthesis and Intracellular uptake of Rhodamine-nucleolipid conjugates into a nanoemulsion vehicle

Anthony Cunha, Geoffrey Prévot, Yannick Mousli, Philippe Barthélémy, Sylvie Crauste-Manciet, Benjamin Dehay and Valérie Desvergnes.

Université de Bordeaux, INSERM, U1212, CNRS UMR 5320, ARNA, ARN : Régulations Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, 33076 Bordeaux CEDEX, France.

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33076 Bordeaux, France.

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Centre Broca Nouvelle-Aquitaine, 146 rue Léo Saignat, 33076 Bordeaux CEDEX France

ABSTRACT: Neurodegenerative diseases represent some of the greatest challenges for both basic science and clinical medicine. Due to their prevalence and lack of known biochemical-based treatments, these complex pathologies represent an increasing societal cost. Increasing genetic and neuropathological evidence point that lysosomal impairment may be a common factor linking these diseases, laying the development of therapeutic strategies aimed at restoring lysosomal function. Here, we propose the design and synthesis of a nucleolipid conjugate as a non-viral chemical nanovector to target specifically neuronal cells and intracellular organelles. Herein, a thymidine appropriately substituted to increase its lipophilicity, was used as a model nucleoside and a fluorophore moiety, covalently bound to the nucleoside, allowed to monitor the nucleolipid internalization in vitro. In order to improve nucleolipid protection and cellular uptake these conjugates were formulated in nanoemulsions. In vitro biological assays demonstrated cell uptake and internalization associated colocalization with lysosomal markers. Overall, this nucleolipid-nanoemulsion based formulation represents a promising drug delivery tool to target the central nervous system, able to bring drugs to restore lysosomal impaired function.

Introduction

The selective filter of the blood brain barrier (BBB) is one of the major obstacle to achieve efficient drug delivery and therapeutic effect to the brain which hampers further treatments for brain-related diseases. Nowadays, innovation in the field of nanosystems allows a better crossing of biological membranes, thus paving the way for new therapeutic approaches. Nucleolipids (NLs) are bifunctional hybrid molecules in which a lipid moiety and a nucleic acid moiety (nucleoside, nucleotide, nucleobase or oligonucleotide) are covalently linked. Exhibiting a wide structural variety, these molecules can be natural such as Algelasine F and Tunicamycin, or made of synthetic origin like the DOTAU. NLs, either natural or synthetic, are interesting for their potential biological activities, including antimicrobial, antifungal, antiviral and antitumor properties, but also for their remarkable ability to self-assemble. Indeed, amphiphilic molecules, such as the DOTAU, can form supramolecular objects like micelles or liposomes, which can be used to deliver DNA, antisense oligonucleotides or siRNA directly into the cells. Because of its similarity to the lipid bilayer of cell membranes, these molecules are expected to cross the plasma membrane without the need of membrane transporters. Considering the benefit of nanoemulsions (NEs) as vehicles for therapeutic agents to target the brain, their combination with NLs, as potential absorption promoter, seemed to be a tantalizing approach to improve the passage of the BBB. Oil-in-water (O/W) NEs, made of submicrometric oily droplets stabilized by a corona of amphiphilic surfactants, present enhanced stability compared to other nanosystems and high loading capacity of hydrophobic drugs or imaging probes. It has also been very recently reported that some NLs, such as a NL radiotracer, was successfully able to permeate the BBB, suggesting that NLs could be promising absorption promoters. In this work, original NEs associated with nucleolipids were developed to enhance the membrane crossing properties for therapeutic purposes and particularly in the context of neurodegenerative diseases. Indeed, previous works have shown that both nanoparticles or NEs loaded with an acidic cargo made of poly(DL-lactide-co-glycolide) (PLGA) were able to induce neuroprotective effects, and following systemic injection, NEs were able to cross the BBB.
Herein, we report the design and synthesis of original NLs and their formulation into NEs to cross the plasma membrane. We show the contribution role of NEs in the uptake and internalization of NLs into neuronal cells in vitro, and colocalization of NLs with lysosomes was observed. These results suggest that lysosomes can be efficiently targeted by the use of these nanotechnology-based systems for drug delivery to brain diseases, in particular of interest in neurodegenerative diseases where lysosomal impairment occurs among others²,²³.

Results and discussion

Design and synthesis of nucleolipidic platforms

Six compounds, among which three original NLs (Figure 1A), were then designed, synthetized and biologically evaluated. Commercially available thymidine was used as a nucleosidic platform and key positions were conveniently functionalized step by step (Figure 1B). A benzyl group was introduced at N-3 position of thymidine to enhance the lipophility of the compound and allow the solubilization in oily phase to provide NE formulation later on. The first NL, compound A, was substituted with a palmity chain at 50 position and a Rhodamine B fluoroprobe at position 3. In NL compound B the lipid chain and the Rhodamine B positions were switched. Thereby, these two lipophilic NLs were formulated into NEs, to carry out in vitro biological assays and evaluate the role of NLs, as well as the position of the different substituents and their influence on the uptake into cells. The third NL (compound C) has been similarly designed by removing the benzyl group to make it water soluble and investigate the role of NEs, and compound E was a Rhodamine-lipid conjugate (Figure 1B).

Figure 1. (A) General structure of nucleolipids. (B) Chemical structure of the different compounds synthetized for this study. (C) Synthetic sequence leading to NL-A.
Compound E was designed to compare its internalization into neuronal cells with that of compound A and investigate the benefits of using a NL rather than a simple lipid chain.

Nucleolipids A and B were prepared in 7 and 5 steps-sequences respectively. The first steps were selective protections of the nucleoside in order to functionalize, thereafter, either position 3’ or 5’. The benzyl group was added on the thymidine N-3 position by a simple alkylation following a procedure using microwave activation previously developed in the laboratory. An esterification reaction between the palmitic acid and the thymidine was performed at the free hydroxyl positions, (position 5’) for compound A and position 3’ for compound B). The protective group was then cleaved before subsequent esterification step with the Rhodamine B moiety (Figure 1C). Compound was then cleaved before subsequent esterification step with the Rhodamine B moiety (Figure 1C). Compound C was obtained through a six-step sequence while compound E required a unique esterification step.

**Nanoemulsions preparation and characterization**

Lipidic nature and plasticity of O/W NEs make them suitable intravenous (I.V.) systems for drug delivery. NEs exhibit a good encapsulation ability for hydrophobic drugs and improve efficiently their stability, I.V. tolerance and bioavailability. Five nanoemulsions were formulated with Medium Chain Triglycerides oil Miglyol® 812N as the oily phase and two surfactants Polysorbate 80 (Tween® 80) and egg phospholipids (Lecithin® E80) (Table 1). NEs-A, NE-B, NE-D and NE-E were prepared in 7 and 5 steps or 5’. The benzyl group was added on the thymidine N-3 position in order to functionalize, thereafter, either position 3’ or 5’. The benzyl group was added on the thymidine N-3 position by a simple alkylation following a procedure using microwave activation previously developed in the laboratory. An esterification reaction between the palmitic acid and the thymidine was performed at the free hydroxyl positions, (position 5’) for compound A and position 3’ for compound B). The protective group was then cleaved before subsequent esterification step with the Rhodamine B moiety (Figure 1C). Compound C was obtained through a six-step sequence while compound E required a unique esterification step.

### Table 1. Composition of loaded NEs with the compound A, B, D or E and the unloaded NE (NE-O). (The amounts of Miglyol® , Lecithin® and Tween® is expressed in % (w/w)).

| NEs composition | NE-O | NE-A | NE-B | NE-D | NE-E |
|-----------------|------|------|------|------|------|
| Miglyol® 812    | 20%  | 20%  | 20%  | 20%  | 20%  |
| Lecithin® E80   | 1.2% | 1.2% | 1.2% | 1.2% | 1.2% |
| Tween® 80       | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
| Compounds mass (mg) | 0 | 10 | 10 | 5 | 7.5 |
| Quantity of compounds (nmol) | 0 | 9.7×10^3 | 9.7×10^3 | 1.0×10^2 | 1.1×10^2 |
| Water q.s | 100 | 100 | 100 | 100 | 100 |

Physico-chemical analysis of the formulations by DLS showed that all five formulations have submicrometer size range (Table 2). All formulations displayed a monodispersed distribution with a polydispersity below 0.2. Zetameter measurement showed a negative zeta potential for the control formulation (NE-O). Indeed, this negative charge is linked with the lecithin E80 surfactant (mixture of phospholipids including negatively charged phospholipids). Interestingly NE-A and NE-B turned out to exhibit positive zeta potential. The same phenomenon was observed with NE-E, the Rhodamine-lipid-based NE, which is also naturally positively charged. Contrariwise, a negative zeta potential was spotted with the Rhodamine B-based formulation (NE-D), because non-lipid conjugated Rhodamine was solubilized in oil phase at the final concentration of 25 mg/ml, suggesting that in this case Rhodamine B was placed inside the oily droplet and not at its surface (Figure 2).

Finally, the colloidal stability of three of these NEs was monitored in Dynamic Light Scattering (DLS) to assess the size of the globules and the index of polydispersity. Moreover, Zeta potential was measured using a zetameter (Figure 2B). Satisfactorily, all formulations proved to remain monodispersed with a mean diameter under 200 nm for at least 14 days, and their zeta potential was consistent over the same time. Moreover NE-A, NE-D NE-E assessed for longer time were found to be stable over 30 days.

### Table 2. Physico-chemical characteristics of unloaded and loaded NEs.

| NEs characteristic | NE-O | NE-A | NE-B | NE-D | NE-E |
|--------------------|------|------|------|------|------|
| Diameter (nm)      | 180.9 | 178.6 | 146.2 | 186.7 | 181.3 |
| Polydispersity Index | 0.167 | 0.177 | 0.140 | 0.181 | 0.183 |
| Zeta potential (mV) | -32.3 | +56.1 | +35.6 | -37.1 | +48.8 |
In vitro cytotoxicity evaluation of nucleolipids-loaded nanoemulsions

Six formulations have been used in vitro to evaluate their respective cytotoxicity onto human neuroblastoma cell lines (BE (2)-M17 cells) during either 24h or 48h. They are the four NEs prepared (NE-A, NE-B, NE-D and NE-E) and two aqueous formulations of compounds C and D (C: NL without the benzyl group and D: Rhodamine B). After 24 or 48 hours of exposure, no significant toxicity was observed except for the formulations Aq-D and NE-E (in a range of 20% to 36%) (Figure 3).

Role of NLs loaded NEs for internalization into lysosomes in vitro

As previously mentioned, lysosomal impairment is a common factor in neurodegenerative diseases. Lysosomes are intracellular acidic compartments that contain hydrolytic enzymes involved in the degradation of intracellular components through several degradation pathways, including endocytosis, phagocytosis, and autophagy. Therefore, to determine if these NE-NL nanovectors can be used as a drug delivery system for neuronal cells, cellular uptake and lysosomal colocalization of the different compounds, labeled with Rhodamine B, were investigated (Figure 4). Foremost, it has been observed that compounds/formulations NE-A, NE-B, NE-E and Aq-C were well internalized into cells, while solely 12% and 6% of cells uptake for formulations NE-D and Aq-D. One possible explanation regarding the low rate of internalization of NE-D and Aq-D, might be explained by the leakage of free Rhodamine outside the oily droplet of the NE, preventing the NE from fully playing its carrier function. Nevertheless, an uptake of 100% was obtained for the two NLs and the Rhodamine-lipid conjugate loaded into NEs (A, B or E), and it has been found out that the rate of NL internalized into cells was greatly enhanced with the use of NE. Indeed, we observed that only 50% of Aq-C, solubilized in water, get through plasma membranes (Figure 4 and 5). Furthermore, each of these compounds labeled with rhodamine (red) colocalized into lysosomes (LAMP2, green).
Figure 4. In vitro biological assessment. Epifluorescence microscopy pictures showing uptake and colocalization evaluation into BE (2)-M17 cells treated with compounds A, B, D and E formulated into NEs and compounds C and D solubilized in water. Nuclei were stained with Hoechst (blue), lysosomes with LAMP2 (green) and compounds A to E are highlighted by the presence of rhodamine B (red). Scale bar: 10 µm.
Consequently, combination of nanoemulsions with properly substituted nucleolipids A and B provided efficient and non-toxic nanovehicles for neuronal cells internalization and subsequent lysosomal colocalization.

Figure 5. Quantification of internalized rhodamine in treated-cells to evaluate the uptake into BE (2)-M17 cells of compounds A, B, D and E formulated into NEs and compounds C and D solubilized in water.

Conclusions

We developed the synthesis of original thymidine-derived NLs bearing the fluorophore rhodamine B to study their biocompatibility and their role as absorption promoter to cross biological membranes. First, we designed lipophilic NLs to afford solubilization into the oily phase of O/W NE. Then, the lipidic chain on sugar moiety and the benzyl group were substituted on the thymine amino group, allowing the formulation of NLs into NEs. The colloidal stability of such NL-NE system was monitored over time by DLS and Zeta potential analysis before carrying out in vitro experiments. Cytotoxicity evaluation of NL-NE complexes on human neuronal cells showed that NLs are fully biocompatible after 24h and 48h of exposure, while other amphiphilic compound, such as Rhodamine-lipid conjugates display cellular toxicity. Uptake evaluations into cells indicate that NL-NE are successfully internalized, highlighting the contribution of NEs as drug delivery vehicles. More importantly, these original NLs bearing a fluorophore moiety are colocalized with lysosomes suggesting that these nanotechnology-based systems can also be efficient tools to target lysosomes, where its impairment has been involved in neurodegenerative diseases. Therefore, these results were promising and pave the way to test in future studies and improve these new NL-NE systems for drug delivery in vivo, offering the possibilities for specific therapeutic solutions targeting pathologies associated with lysosomal impairment.

EXPERIMENTAL SECTION

General information

All reactions were carried out under an argon atmosphere. Yields refer to chromatographically and spectroscopically (1H-NMR) homogeneous materials, unless otherwise stated. All reagent-grade chemicals were obtained from commercial suppliers and were used as received, unless otherwise stated.

1H-NMR and 13C-NMR were recorded on a Bruker Avance 300 (1H: 300 MHz, 13C: 75.46 MHz) spectrometer using residual CHCl3 as internal reference (7.26 ppm) and at 293K unless otherwise indicated. The chemical shifts (δ) and coupling constants (J) are expressed in ppm and Hz respectively. The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = broad. FT-IR spectra were recorded on a Perkin-Elmer FT spectrometer Spectrum two (UATR two). For the ESI HRMS analyses, a Waters Micromass ZQ instrument equipped with an Electrospray source was used in the positive and/or negative mode. MALDI TOF mass spectrometric analyses were performed on a PerSeptive Biosystems Voyager-De Pro MALDI mass spectrometer in the Linear mode using 3,4-dihydroxybenzoic acid as the matrix. Analytical thin layer chromatography was performed using silica gel 60 F254 pre-coated plates (Merck) with visualization by ultraviolet light, potassium permanganate or sulfuric acid. Flash chromatography was performed on silica gel (0.043-0.063 mm).

Procedure for compound A synthesis

Synthesis of compound 1. To a solution of thymidine (1 eq., 6 g, 24.77 mmol) in pyridine (118 mL) and under argon are sequentially added the TBDMSCl (1.2 eq., 4.48 g, 29.72 mmol) and DMAP (spatula tip). The mixture is stirred overnight at room temperature to completion. The reaction is then quenched by addition of NaHCO3 (10 mL, aq.) and diluted with water (10 mL). The aqueous phase is extracted three times with DCM (3x30 mL), and the combined organic phases are dried over Na2SO4 before concentration to dryness under vacuum. The resulting crude is purified by flash chromatography on silica gel (Pentane/EtOAc, 70/30) in order to obtain the expected compound 1 as a white powder (7.68 g, 21.55 mmol, 87%). NMR data are consistent with literature. Rf : 0.24 (Pentane/EtOAc, 70/30). IR (ATR) 3 (cm-1) : 3549, 3167, 2929, 2855, 1696, 1471, 1257, 1120, 832, 779.

Synthesis of compound 2. 1) To a solution of 1 (1 eq., 14.7 g, 41.21 mmol) in DMF (88 mL) and under argon are sequentially added the imidazole (1.2 eq., 3.37 g, 49.54 mmol) followed by TBDPSCI (1.2 eq., 12.88 mL, 49.54 mmol). The mixture is stirred overnight at room temperature to completion. The mixture is then diluted with toluene (100 mL) and DMF was coevaporated under vacuum to obtain a yellow oil. The oil is diluted in diethyl ether (10 mL) and the white precipitate formed is filtered, and washed with an aqueous solution of NaCl. The organic phase is dried over Na2SO4 before concentration to dryness under vacuo. 16 was obtained as a yellow oil. 2) To a solution of 16 in methanol (80 mL) and under argon is added para-toluenesulfonic acid monohydrate (0.471 g, 2.477 mmol). The mixture is stirred overnight at room temperature to completion. The methanol is then evaporated under vacuum to obtain a yellow oil. The crude product diluted with EtOAc (30 mL) and the organic phase is washed three times with NaHCO3 (10 mL, aq.) and brine (3x20 mL). The organic phase is dried over Na2SO4 before concentration to dryness under vacuo. The resulting crude is purified by flash chromatography on silica gel (Petroleum Ether/EtOAc, 50/50) in order to obtain the expected compound 2 as a white powder (6.90 g, 14.36 mmol, 58% over two steps). Rf : 0.29 (Petroleum ether/EtOAc, 50/50). 1H NMR (300MHz, CDCl3) δ ppm : 9.18 (bs, 1H, NH), 7.59-7.69 (m, 4H, H Ar), 7.34-7.50 (m, 6H, H Ar), 7.30 (d, J = 1.2Hz 1H, Hg), 6.26 (dd, J = 6.0Hz, 7.8Hz, 1H, Hf), 4.41-4.80 (m, 1H, Ha), 3.94-4.00 (m, 1H, Hb), 3.62 (dd, J = 2.4Hz, 12.0Hz, 1H, Hg), 3.24 (s, 2H, Hb), 2.43 (bs, 1H, OH), 2.26 (ddk, J = 3.0Hz, 6.0Hz, 13.2Hz, 1H, Ha), 2.04-2.22 (m, 1H, Hf), 1.82 (d, J = 1.2Hz, 3H, Hg), 1.08 (s, 9H, 1Bu). 13C NMR (75.46MHz, CDCl3) δ ppm : 164.0 (Cg), 150.5 (Cf), 136.9 (Cg), 135.8 (CH Ar), 133.4 (Cq Ar), 133.3 (Cq Ar), 132.0 (CH Ar), 130.2 (CH Ar), 128.0 (CH Ar), 111.0 (Cg), 87.8 (Cg), 86.6 (Cg), 73.1 (Cg), 62.1 (Cg), 40.4 (Cq Ar), 27.0 (CH2 Bu), 19.1 (Cq Bu), 12.5 (Cf). IR (ATR) 3 (cm-1) : 2932, 1682, 1471, 1274, 1104, 1031, 740, 702.
Synthesis of compound 3. To a solution of 2 (1 eq., 1.208 mmol) in anhydrous DMF (10 mL) and under argon atmosphere, NaN₃ (1.2 eq., 0.135 g, 3.37 mmol) is added and the reaction mixture is stirred in a microwave oven (2 min, 40°C, 200W). The mixture is stirred further for 60 min and then diluted with water (10 mL). The aqueous phase is extracted three times with DCM (3x10 mL) and the combined organic phases are dried over Na₂SO₄ before concentration to dryness under vacuum. The resulting crude is purified by flash chromatography on silica gel (Pentane/AcOEt, gradient 90/10 to 70/30) in order to obtain the expected compound 5 (0.190 g, 3.33x10⁻³ mmol, 83%).

**Synthesis of compound 4.** To a solution of 3 (1 eq., 0.160 g, 2.80x10⁻³ mmol) in DCM (1.6 mL) and under argon are sequentially added the palmitic acid (1.2 eq., 0.086 g, 3.36x10⁻³ mmol), the EDC.HCl (1 eq., 0.052 g, 2.71x10⁻³ mmol) and the DMAP (0.3 eq., 0.010 g, 8.4x10⁻⁴ mmol). The mixture is stirred 48h at room temperature. The reaction is then quenched by addition of NH₄Cl (5 mL, aq.) and diluted with water (10 mL). The aqueous phase is extracted three times with DCM (3x10 mL) and the combined organic phases are dried over Na₂SO₄ before concentration to dryness under vacuum. The resulting crude is purified by flash chromatography on silica gel (Pentane/AcOEt, 90/10) in order to obtain compound 4 (0.138 g, 1.70x10⁻⁰ mmol, 63%) as a white foam. 

**Synthesis of compound 5.** To a solution of 4 (1 eq., 0.326 g, 4.03x10⁻⁰ mmol) in THF (4.54 mL) and under argon is added the TBAF (1M in THF, 0.403 mL) at 0°C. The mixture is stirred 2 hours at 0°C. The reaction is then quenched by addition of water (5 mL) and the mixture is warmed to room temperature before addition of DCM (10 mL). The aqueous phase is extracted three times with DCM (3x10 mL) and the combined organic phases are dried over Na₂SO₄ before concentration to dryness under vacuum. The resulting crude is purified by flash chromatography on silica gel (Pentane/AcOEt, gradient 90/10 to 70/30) in order to obtain the expected compound 5 (0.190 g, 3.33x10⁻³ mmol, 83%).

**Synthesis of compound A.** To a solution of 5 (1 eq., 0.190 g, 3.33x10⁻³ mmol) in DCM (1.9 mL) and under argon are sequentially added the benzyl bromide (1.2 eq., 0.191 g, 3.99x10⁻³ mmol), EDC.HCl (1 eq., 0.062 g, 3.23x10⁻³ mmol) and DMAP (0.3 eq., 0.012 g, 9.99x10⁻⁴ mmol). The mixture is stirred 48h at room temperature. The reaction is then quenched by addition of NH₄Cl (5 mL, aq.) and diluted with water (10 mL). The aqueous phase is extracted three times with DCM (3x10 mL), and the combined organic phases are dried over Na₂SO₄ before concentration to dryness under vacuum. The resulting crude is purified by flash chromatography on silica gel (DCM/Methanol, 95/5) in order to obtain the expected compound A as a purple powder (0.132 g, 1.28x10⁻⁴ mmol, 40%). 

**General procedure for NEs preparation.** Lipoid® E80 (Lipoid GmbH, Ludwigshafen, Germany) was dispersed in heated (i.e. 70°C) oil phase Miglyol® 812N (IOI Oleo GmbH, Hamburg, Germany) using ultrasound delivery and dispersed in heated (i.e. 70°C) oil phase Miglyol® 812N (IOI Oleo GmbH, Hamburg, Germany) using ultrasound delivered from an ultrasound device (Biodispersion B, 0.11 eq., 1.01x10⁻¹ mol) and O=C

**IR (ATR) (3 cm⁻¹)**: 3363, 2918, 2980, 1697, 1621, 1470, 1178, 1092, 710. HRMS (ESI) [M+H]⁺: calecd = 571.37416, found = 571.37405.

**IR (ATR) (3 cm⁻¹)**: 3363, 2918, 2980, 1697, 1621, 1470, 1178, 1092, 710. HRMS (ESI) [M+H]⁺: calecd = 571.37416, found = 571.37405.
in oil and surfactant mixture. Hydrophilic surfactant Tween® 80 (SEPPIC, Paris, France) was dispersed in heated (i.e. 70°C) water phase (Milli-Q water). The emulsification was obtained by adding the water phase to the oil phase thanks to phase inversion method. Homogenization was performed using a sonication probe (Sonic Vibra Cell - VC 250) for 10 min to obtain submicron size range oil droplets. Prior to in vitro experiments, formulation osmolality was adjusted with the addition of Glycerol (Coopération pharmaceutique française) at 2% and pH was adjusted close to physiological value using sodium hydroxide 0.1 N.

**NEs characterization and stability**

Granulometric profile of NE were characterized by Dynamic Light Scattering (DLS), using Malvern Instruments (Zetasizer Nano ZS). NE were diluted at 1:1000 (v/v) and the average size and the polydispersity index were determined on 3 independent measurements performed at 25 °C. To analyze the Zeta potential, NEs were diluted at 1:1000 (v/v) and measurements were performed using Zetasizer Nano ZS coupled with Folded Capillary Cell (DTS1060) from Malvern Instruments. Short term stability assessment of the NE was performed during 1 month by checking the lack of visual creaming or phase separation and by checking the granulometric profiles and zeta potential.

**Cell culture and cell viability assay**

Cell lines BE (2)-M17 (human neuroblastoma) were obtained from ATCC (CRL-2267) and grown in OPTIMEM (Life Technologies, 31985-047) adding 10% fetal bovine serum (Sigma-Aldrich) and 1% penicillin/streptomycin. For all experiments, NE solutions were used as freshly prepared and cells were grown at 70% to 80% confluence per well. Cells permeabilization and blocking steps are realized by addition of a mixture compose with PBS. Cells were then incubated for 8 min at room temperature with 8µM Hoechst 33342, 450 µL of normal goat serum and 225 µL of triton. Lysosome were marked with the LAMP2 (Mx, H4B4) antibody overnight at 4°C and staining was revealed with appropriate secondary antibody conjugated with GAM 488 (Life Technologies). For cytoplasm and nuclei staining, the cells were incubated for 8 min at room temperature with 8µM Hoechst dye (ThermoFisher Scientific, #3342) prior to mounting. Slices were air-dried and mounted on #1.5 coverslips with Dako fluorescent mounting medium and left to dry overnight in darkness.

Images stacks (pixel size ~100 nm, z-step 0.3 µm) were acquired on a Leica TCS SP8 microscope laser scanning confocal microscope (Leica Microsystems) using a 63X Plan Apo CS oil immersion objective. Rhodamine B was detected by using excitation wavelength of 568 nm (DPSS laser) and with a detection window between 570 and 590 nm. Lysosome were detected by using excitation wavelength of 488 nm (argon laser) and with a detection window between 545 and 605 nm. Cells without loaded-nanoemulsion treatments were used in parallel as autofluorescence controls using the corresponding excitation and detection wavelengths. Images were analyzed with LAS AF v2.6 acquisition software equipped with HCS-A module (Leica Microsystems). Rhodamine B intensity relative to cell surface was quantified with Definiens XD Developer v2.5 software (Definiens). Colocalization, fluorescence profiles, orthogonal projections and maximal intensity projections were obtained with the ImageJ (NIH) distribution Fiji.

**Statistical analysis**

Statistical analysis was performed in GraphPad Prism 6 software. For functional assays, statistical significance of the data was evaluated after the calculation of a one-way analyses of variance (ANOVA) followed by Tukey’s multiple comparison test. The level of significance was set at p < 0.05.

**Supporting Information**

Synthetic procedures and characterization of compounds 1, 2, 3, 4, 5, A, 6, 7, 8, B, 9, 10, C, and E.

**Author contributions**

A.C., G.P. and Y.M. carried out experiments. P.B., S.C.-M., V.D. and B.D. designed the experiments, analyzed the data and wrote the manuscript. P.B. provided critical tool and reagents. P.B. and B.D. secured the funding. All authors read and approved the manuscript.

**Acknowledgements**

This work was supported by Fondation de France Grant number 00066525 and an IDEX Emergence Grant number OPE-2018-410 (B.D.). A.C. is a recipient of a MESR fellowship (France). G.P. has been supported by a MESR fellowship and the Fondation de France. The LABEX Brain, the University of Bordeaux and the Centre National de la Recherche Scientifique provided infrastructural support.

**Conflicts of interest**

There are no conflicts to declare.

**References**

(1) Furtado, D.; Björnalm, M.; Aytón, S.; Bush, A. I.; Kempe, K.; Canuso, F. Overcoming the Blood Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Adv. Mater. 2018, 30 (46). https://doi.org/10.1002/adma.201801362.

(2) Teleanu, D. M.; Negut, I.; Grumezescu, V.; Grumezescu, A. M.; Teleanu, R. I. Nanomaterials for Drug Delivery to the Central Nervous System. Nanomaterials 2019, 9 (3). 1118. https://doi.org/10.3390/nano9030371.

(3) Cho, C. F.; Wolfe, J. M.; Fadzen, C. M.; Calligaris, D.; Hornburg, K.; Chiocca, E. A.; Agar, N. Y. R.; Pentelute, B. L.; Lawler, S. E. Blood-Brain-Barrier Spheroids as an In Vitro Screening Platform for Brain-Penetrating Agents. Nat. Commun. 2017, 8, 1114. https://doi.org/10.1038/ncomms15623.

(4) Teleanu, D. M.; Chircov, C.; Grumezescu, A. M.;
Teleanu, R. I. Neuronanomedicine: An up-to-Date Overview. *Pharmaceutics* 2019, 11 (3), 111.23. https://doi.org/10.3390/pharmaceutics11030101.

(5) Tang, W.; Fan, W.; Lau, J.; Deng, L.; Shen, Z.; Chen, X. Emerging Blood-Brain-Barrier-Crossing Nanotechnology for Brain Cancer Theranostics. *Chem. Soc. Rev.* 2019, 48 (11), 2967–3014. https://doi.org/10.1039/c8cs00805a.

(6) Baille, J.; Desvergnes, V.; Hamoud, A.; Lattuguez, L.; Barthélémy, P. Lipid and Nucleic Acid Chemistries: Combining the Best of Both Worlds to Construct Advanced Biomaterials. *Adv. Mater.* 2018, 30 (11), H124. https://doi.org/10.1002/adma.201705078.

(7) Takatsuki, A.; Tamura, G. Tunicamycin, a New Antibiotic. II. Some Biological Properties of the Antiviral Activity of Tunicamycin. *J. Antibiot.* (Tokyo), 1971, 24 (4), 224–231. https://doi.org/10.7164/antibiotics.24.224.

(8) Awasthi, N.; Zhang, C.; Schwarz, A. M.; Hinz, S.; Wang, C.; Williams, N. S.; Schwarz, M. A.; Schwarz, R. E. Comparative Benefits of Nab-Paclitaxel over Gemcitabine or Polysorbate-Based Docetaxel in Experimental Pancreatic Cancer. *Carcinogenesis* 2013, 34 (10), 2361–2369. https://doi.org/10.1093/carcin/bgt227.

(9) Chabaud, P.; Camplø, M.; Payet, D.; Serin, G.; Moreau, L.; Barthélémy, P.; Gristaff, M. W. Cationic Nucleoside Lipids for Gene Delivery. *Bioconjug. Chem.* 2006, 17 (2), 4661–472. https://doi.org/10.1021/bc050162q.

(10) van Tiel, F. H.; Boere, W. A.; Harmsen, T.; Kraaijeveld, C. A.; Snippe, H. Determination of Inhibitory Concentrations of Antiviral Agents in Cell Culture by Use of an Enzyme Immunoassay with Virus-Specific Peroxidase-Labeled Monoclonal Antibodies. *Antimicrob. Agents Chemother.* 1985, 27 (5), 802–805. https://doi.org/10.1128/aac.27.5.802.

(11) Riccardi, C.; Musumeci, D.; Irace, C.; Paduano, L.; Montesarchio, D. Ru III Complexes for Anticancer Therapy: The Importance of Being Nucleophilic. *European J. Org. Chem.* 2017, 2017 (7), 11001–1119. https://doi.org/10.1002/ejoc.201600943.

(12) Simeone, L.; Mangiapia, G.; Irace, C.; Di Pascale, A.; Colonna, A.; Ortona, O.; De Napoli, L.; Montesarchio, D.; Paduano, L. Nucleolipid Nanovectors as Molecular Carriers for Potential Applications in Drug Delivery. *Mol. Biosyst.* 2011, 7 (11), 3075–3086. https://doi.org/10.1039/c1mb05143a.

(13) Prévot, G.; Kauss, T.; Lorenzato, C.; Gaubert, A.; Larivières, M.; Baille, J.; Laroche-Traineau, J.; Jacobin-Valat, M. J.; Adumeau, L.; Monet, S.; et al. Iron Oxide Core–Oil-in-Water Nanoemulsion as Tracer for Atherosclerosis MPI and MRI Imaging. *Int. J. Pharm.* 2017, 532 (2), 669–676. https://doi.org/10.1016/j.ijpharm.2017.09.010.

(14) Prokhorov, D. I.; Sariev, A. K.; Abramov, D. A.; Voronina, T. A.; Kapitsa, I. G.; Zhuravko, A. S.; Shiraeva, M. V.; Kaplan, A. P.; Seifulla, R. D. Experimental Investigation of Pharmacodynamics and Pharmacokinetics of Carbamazepine Nanoemulsion. *Bull. Exp. Biol. Med.* 2014, 157 (6), 742–746. https://doi.org/10.1007/s10517-014-2657-z.

(15) Kumar, S.; Ali, J.; Baboota, S. Design Expert *Supported Optimization and Predictive Analysis of Seleagine Nanoemulsion via the Olfaactory Region with Enhanced Behavioural Performance in Parkinson’s Disease.* Nanotechnology 2016, 27 (43), 435101. https://doi.org/10.1088/0957-4484/27/43/435101.

(16) Jaiswal, M.; Dudhe, R.; Sharma, P. K. Nanoemulsion: An Advanced Mode of Drug Delivery System. *3 Biotech* 2015, 5 (2), 123–127. https://doi.org/10.1007/s13205-014-0214-8.

(17) Gonzales, J.; Kossatz, S.; Roberts, S.; Pirovano, G.; Brand, C.; Pérez-Medina, C.; Donabedian, P.; de la Cruz, M. J.; Mulder, W. J. M.; Reiner, T. Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer. *Bioconjug. Chem.* 2018, 29 (11), 3776–3782. https://doi.org/10.1021/acs.bioconjchem.8b00640.

(18) Gianella, A.; Jarzyna, P. A.; Mani, V.; Ramachandran, S.; Calcagno, C.; Tang, I.; Kann, B.; Dijk, W. J. R.; Thijsen, V. L.; Griffioen, A. W.; et al. Multifunctional Nanoemulsion Platform for Imaging Guided Therapy Evaluated in Experimental Cancer. *ACS Nano* 2011, 5 (6), 4421–4433. https://doi.org/10.1021/nn103336a.

(19) Swastika; Chaturvedi, S.; Kaul, A.; Hazari, P. P.; Jha, P.; Pal, S.; Lal, S.; Singh, B.; Barthélémy, P.; Mishra, A. K. Evaluation of BBB Permeable Nucleolipid (NLDPU): A Di-C15-Ketalised Palmitone Appended Uridine as Neuro-Tracer for SPECT. *Int. J. Pharm.* 2019, 565 (December 2018), 269–282. https://doi.org/10.1016/j.ijpharm.2019.04.074.

(20) Prévot, G.; Soria, F. N.; Thiolat, M. L.; Daniel, J.; Verlhac, J. B.; Blanchard-Desce, M.; Bezard, E.; Barthélémy, P.; Crauste-Manciet, S.; Dehay, B. Harnessing Lysosomal PH through PLGA Nanoemulsion as a Treatment of Lysosomal-Related Neurodegenerative Diseases. *Bioconjug. Chem.* 2018, 29 (12), 4083–4089. https://doi.org/10.1021/acs.bioconjchem.8b00697.

(21) Bourdenx, M.; Daniel, J.; Genin, E.; Soria, F. N.; Blanchard-Desce, M.; Bezard, E.; Dehay, B. Nanoparticles Restore Lysosomal Acidification Defects: Implications for Parkinson and Other Lysosomal-Related Diseases. *Autophagy* 2016, 12 (3), 472–483. https://doi.org/10.1080/15548627.2015.1136769.

(22) Dehay, B.; Martinez-Vicente, M.; Caldwell, G. A.; Caldwell, K. A.; Yue, Z.; Cookson, M. R.; Klein, C.; Vila, M.; Bezard, E. Lysosomal Impairment in Parkinson’s Disease. *Movement Disorders*. NIH Public Access June 2013, pp 725–732. https://doi.org/10.1002/mds.25462.

(23) Bonam, S. R.; Wang, F.; Muller, S. Lysosomes as a Therapeutic Target. *Nat. Rev. Drug Discov.* 2019, 18 (1), 73–73. https://doi.org/10.1038/s41573-019-0036-1.

(24) Hamoud, A.; Barthélémy, P.; Desvergnes, V. An Organocatalyzed Stetter Reaction as a Bio-Inspired Tool for the Synthesis of Nucleic Acid-Based Bioconjugates. *Org. Biomol. Chem.* 2018, 16 (10), 1760–1769. https://doi.org/10.1039/c8ob00192h.
(25) Piorkowski, D. T.; McClements, D. J. Beverage Emulsions: Recent Developments in Formulation, Production, and Applications. *Food Hydrocoll.* **2014**, *42*, 51–41. https://doi.org/10.1016/j.foodhyd.2013.07.009.

(26) Luzio, J. P.; Pryor, P. R.; Bright, N. A. Lysosomes: Fusion and Function. *Nat. Rev. Mol. Cell Biol.* **2007**, *8* (8), 622–632. https://doi.org/10.1038/nrm2217.

(27) Lübke, T.; Lobel, P.; Sleat, D. E. Proteomics of the Lysosome. *Biochim. Biophys. Acta - Mol. Cell Res.* **2009**, *1793* (4), 625–635. https://doi.org/10.1016/j.bbamcr.2008.09.018.